EUVIMEDEUVIMED entdecken
Crossref

Association of Serum Thyroxine and Atrial Fibrillation in Patients on Levothyroxine

Maria Kravchenko iD, Whitney Forbes, Sky Graybill iD

Military Medicine · 2025

DOI: 10.1093/milmed/usae324 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Military Medicine, 2025. Verfasst von Maria Kravchenko und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Brooke Army Medical Center and Wilford Hall Ambulatory Surgical Center, San Antonio, TX 78234, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Thyroxine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Excess thyroid hormone is a well-documented risk factor for the development of atrial fibrillation (AF). The purpose of the study is to assess incidence of AF in patients taking levothyroxine for hypothyroidism and correlate it with biochemical thyroid function. Materials and Methods This was a retrospective cohort study of patients aged 18 years and older who were treated with levothyroxine. Exclusion criteria were pre-existing diagnosis of AF and use of amiodarone in the prior year. Patients were followed 2012 through 2019 and stratified into 4 groups based on mean thyroid-stimulating hormone (TSH) value or mean fT4 value in 2012. Primary outcome was incidence of AF. Rates of AF between groups were assessed via Poisson regression with control of underlying confounders.

Results

Of 21,035 patients, 1091 (5.2%) developed AF during follow-up. Thyroid-stimulating hormone at baseline was not significantly associated with incident AF. Higher fT4 levels at baseline were associated with increased AF risk in age- and sex-adjusted analyses (hazard ratio 1.22; 95% CI, 1.03-1.44) for the highest quartile versus the lowest quartile of fT4.

Conclusions

In hypothyroid patients treated with levothyroxine, higher circulating fT4 levels are associated with increased risk of incident AF. There is no association of serum TSH with risk of AF. In patients at risk for AF, consideration should be given to avoiding fT4 levels in the highest quartile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationThyroxineHumansFemaleMaleRetrospective StudiesMiddle AgedAgedHypothyroidismIncidenceCohort StudiesRisk FactorsAdultThyrotropin

Substanzen

ThyroxineThyrotropin

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology, Brooke Army Medical Center and Wilford Hall Ambulatory Surgical Center, San Antonio, TX 78234, USA.
  • Maryland Metabolic Institute, Ascension Saint Agnes Hospital, Baltimore, MD 21229, USA.
  • Defense Health Agency, Lackland Air Force Base, San Antonio, TX 78234, USA.

ORCID-Profile: Maria Kravchenko, Sky Graybill

Zitieren

APA

Kravchenko, M., Forbes, W., & Graybill, S. (2025). Association of Serum Thyroxine and Atrial Fibrillation in Patients on Levothyroxine. Military Medicine. https://doi.org/10.1093/milmed/usae324

Vancouver

Kravchenko M, Forbes W, Graybill S. Association of Serum Thyroxine and Atrial Fibrillation in Patients on Levothyroxine. Military Medicine. 2025. doi:10.1093/milmed/usae324

BibTeX
@article{Kravchenko2025,
  author = {Kravchenko, Maria and Forbes, Whitney and Graybill, Sky},
  title = {Association of Serum Thyroxine and Atrial Fibrillation in Patients on Levothyroxine},
  journal = {Military Medicine},
  year = {2025},
  doi = {10.1093/milmed/usae324}
}
Kostenlos starten →